NON-INFERIORITY

作品数：33被引量：94H指数：4
导出分析报告
相关领域：医药卫生更多>>
相关作者：陈豪陈伟权更多>>
相关机构：华南师范大学更多>>
相关期刊：《Journal of the National Cancer Center》《International Journal of Ophthalmology(English edition)》《Chinese Medical Journal》《实用休克杂志（中英文）》更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Therapeutic effectiveness of different machines in intense pulsed light treatment of meibomian gland dysfunction
《Advances in Ophthalmology Practice and Research》2024年第4期182-188,共7页Zhenwei Qin Yirui Zhu Jiale Lu Lin Lin Yanan Huo Haoyu Wang Chen Qiao Xiangxi Chen Jianhua Wu Qingyan Zeng Xiuming Jin 
supported by the National Natural Science Foundation of China:[grant numbers:82171013,81870624];Major Science and Technology Projects of Zhejiang Province[grant numbers:2022C03173].
Purpose:This study aimed to determine the therapeutic effectiveness of different machines in intense pulsed light(IPL)treatment of meibomian gland dysfunction(MGD).Methods:213 subjects diagnosed with MGD underwent thr...
关键词：MGD IPL Non-inferiority analysis Dual filter system 
Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children:A multicenter,non-inferiority,prospective,randomized controlled trial
《Acta Pharmaceutica Sinica B》2024年第12期5186-5200,共15页Qinhua Fan Chongming Wu Yawei Du Boyang Wang Yanming Xie Zeling Zhang Wenquan Su Zizhuo Wang Changchang Xu Xueke Li Ying Ding Xinjiang An Jing Chen Yunying Xiao Rong Yu Nan Li Juan Wang Yiqun Teng Hongfen Lv Nian Yang Yuling Wen Xiaoli Huang Wei Pan Yufeng Liu Xueqin Xi Qianye Zhao Changshan Liu Jian Xu Haitao Zhang Lie Zhuo Qiangquan Rong Yu Xia Qin Shen Shao Li Junhong Wang Shengxian Wu 
the National Key Research and Development Program of the Ministry of Science and Technology of China in 2018,“Research on Modernization of TCM”project,“Demonstration Study on Evidence-based Evaluation and Effect Mechanism of Ten Chinese Patent Medicines and Classic Famous Prescriptions in the Treatment of Major Diseases after marketed”(2018YFC1707400 and 2018YFC17074101,China);National Administration of Traditional Chinese Medicine(GZY-KJS-2024-03,China).
The comparison between traditional Chinese medicine Jinzhen oral liquid(JZOL)and West-ern medicine in treating children with acute bronchitis(AB)showed encouraging outcomes.This trial eval-uated the efficacy and safet...
关键词：Acute bronchitis Jinzhen oral liquid Complementary and alternative medicine Clinical trial Network target analysis 
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial
《四川生理科学杂志》2024年第11期2460-2460,共1页David Erlinge 
Background:Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention(PCI)remain a challenge.A bioadaptor is a novel implant that addresses this issue by restoring the h...
关键词：IMPLANT coronary CONTEMPORARY 
Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours(RAISE):rationale and design of a multicentre,prospective,randomised,open-label,blinded-endpoint,controlled phase 3 non-inferiority trial
《Stroke & Vascular Neurology》2024年第5期568-573,共6页Shuya Li Hong-Qiu Gu Hongguo Dai Guozhi Lu Yongjun Wang 
National Natural Science Foundation of China(U20A20358);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M 5-029);Beijing Municipal Science&Technology Commission(No.2221100007422050);National Natural Science Foundation of China(U20A20358);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M 5-029);Beijing Municipal Science&Technology Commission(No.2221100007422050).
Background and purpose Reteplase is the third generation of alternative thrombolytic agent.We hypothesis that reteplase will be non-inferior to alteplase in achieving excellent functional outcome at 90 days among elig...
关键词：centre ENDPOINT random 
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer:a multicenter,open-label,non-inferiority,randomized controlled trial
《Journal of the National Cancer Center》2024年第2期135-141,共7页Rong Li Hongping Zhang Qingshui Li Guangwen Yuan Yanjie Zhou Rutie Yin He Wang Chunyan Wang Yi Huang Wei Wang Xiaojian Yan Lingying Wu Qi Zhou 
funded by the Optimization Study of Treatment Regimen and Clinical Practice in Ovarian Cancer(grant number:2016YFC1303702).
Background:The paclitaxel liposome formulation,encapsulating paclitaxel within a phospholipid bilayer,ad-dresses the insolubility of traditional paclitaxel formulations,thereby reducing toxicity without compromising i...
关键词：Ovarian cancer Paclitaxel liposome First-line chemotherapy Efficacy Safety 
Efficacy and safety of bilastine vs.levocetirizine for the treatment of chronic idiopathic urticaria:A multicenter,double-blind,double-dummy,phase III,non-inferiority,randomized clinical trial被引量：1
《Chinese Medical Journal》2024年第12期1480-1482,共3页Xue Chen Xiuping Han Bo Cheng Hui Li Lingling Liu Songmei Geng Linfeng Li Jie Li Qing Guo Guoyi Zhang Hong Fang Jianzhong Zhang 
To the Editor:Chronic urticaria,prevalent globally and increasing in China,predominantly affects young and middle-aged women,impacting their quality of life(QoL).[1]Standard treatment involves second-generation H1 ant...
关键词：TREATMENT DOUBLE globally 
Corrigendum:Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure:A randomized,open-label,parallel-group,non-inferiority phase III trail
《Chronic Diseases and Translational Medicine》2024年第1期81-81,共1页
In the article titled,“Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure:A randomized,open-label,parallel-group,non-inferiority ...
关键词：INJECTION ANEMIA ALFA 
A randomized,controlled,open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China
《Frontiers of Medicine》2024年第1期98-108,共11页Jie Jin Zhihua Ran Emanuele Noseda Bernard Roubert Matthieu Marty Anna Mezzacasa Udo Michael Göring 
support was provided by Vifor Pharma,Glattbrugg,Switzerland.
Iron deficiency(ID)and ID anemia(IDA)pose significant public health concerns in China.Although iron sucrose(IS)treatment is well-established in the country,ferric carboxymaltose(FCM)offers the advantage of higher dose...
关键词：iron deficiency ANEMIA intravenous iron ferric carboxymaltose iron sucrose Hb response early response 
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction:A randomized non-inferiority trial被引量：4
《Chinese Medical Journal》2024年第3期312-319,共8页Xingshan Zhao Yidan Zhu Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu Shubin Qiao 
supported by the Guangzhou Recomgen Biotech Co.,Ltd.The funder had no role in the design and conduct of the study;collection,management,analysis,and interpretation of the data
Background:A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator(rhTNK-tPA)has previously shown its preliminary efficacy in ST elevation myocardial infarction(STEMI)patients.This study w...
关键词：Thrombolytic therapy rhTNK-tPA Randomized controlled trial ST elevation myocardial infarction 
Pars plana vitrectomy for retinal detachment using perfluoro-n-octane as intraoperative tamponade:a multicenter,randomized,non-inferiority trial
《International Journal of Ophthalmology(English edition)》2024年第1期82-91,共10页Xin Shi Wei-Jun Wang Ying Fan Hai-Yun Liu Hong Wang Yu-Hui Chen Ao Rong Zhi-Feng Wu Xun Xu Kun Liu 
Supported by the Program of Shanghai Academic/Technology Research Leader(No.21XD1402700);the Clinical Research Plan of Shenkang Hospital Development Center of Shanghai(No.SHDC2022CRD001).
AIM:To evaluate the efficacy and safety of perfluoro-n-octane(PFO)for ophthalmic surgery versus F-Octane as an intraoperative tamponade in pars plana vitrectomy(PPV)in management of retinal detachment.METHODS:This mul...
关键词：perfluoro-n-octane vitreoretinal surgery intraocular tamponade ophthalmic surgery retinal detachment 
全选清除导出
共4页<1234>
检索报告 对象比较 聚类工具 使用帮助 返回顶部